Microbix Biosystems Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cameron L. Groome
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 265 Watline Avenue Mississauga ON Canada L4Z 1P3
- IPO Date
- Jan 8, 2021
- CIK
- 0001472866
- Website
- microbix.com
- Similar Companies
- Business
- Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for the global diagnostics industry, including infectious disease antigens as key ingredients for immunoassays; quality assessment products (QAPs™) such as REDx™FLOQ®, PROCEEDx®, and ONBOARDx™ for proficiency testing, assay validation, and workflow quality control covering respiratory viruses (SARS-CoV-2, RSV, Flu A/B, parainfluenza, adenovirus), high-risk HPV, STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium), genital ulcers (HSV 1/2, VZV, Treponema pallidum, Monkeypox), gastrointestinal pathogens (C. difficile, Campylobacter, Rotavirus), and vaginal infections; DxTM™ viral transport medium and control elution buffers for specimen collection and stabilization; vial filling services with capacities up to 60,000 vials per day; and Kinlytic® urokinase, a biologic thrombolytic for blood clot clearance. The company serves over 100 multinational diagnostics firms, clinical labs, and accreditation agencies across North America, Europe, Asia-Pacific, and internationally, with products registered with FDA, Health Canada, EU IVDR, UK MHRA, and Australian TGA. Founded in 1988 and headquartered in Mississauga, Ontario, Canada, Microbix operates from three adjacent facilities supporting antigen production, medical device manufacturing, and R&D. Recent developments include a November 2025 partnership with SEKISUI Diagnostics for QAPs supporting COVID/Flu point-of-care assays on the Metrix® platform; launch of QUANTDx™ characterized reference materials; supply agreement with Bulgaria’s NCIPD for pathogen seedstocks; collaborations with EMQN for genetic-test EQA programs on Clopidogrel metabolism and antibiotic-induced hearing loss; execution of Sequel Pharma agreements advancing Kinlytic® toward US re-approval with US$4.0 million in milestones received since May 2023; $2.4 million from warrant exercises; recombinant antigen production expansion; multiple grants including $3.6 million from FedDev Ontario (repayment from 2026) and Ontario Together Fund; Normal Course Issuer Bids repurchasing shares; and Q1 fiscal 2025 revenues of $6.0 million with 40% recurring growth and net earnings of $0.9 million.
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
Microbix Reports Results for H1 & Q2 2026
Microbix Schedules Release of Results for Q2 Fiscal 2026
Microbix Product Results Being Presented at 2026 PASCV
Microbix Engages with Diagnostics Industry Experts
Microbix Presenting at the 2026 Bloom Burton Conference
Microbix Exhibiting & Presenting at ESCMID Global 2026
Microbix Announces Annual Meeting Voting Results
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
Microbix Presents Reference-Material Innovations at EUROGIN
Microbix's Clot-Buster Drug Project Advances
Microbix Announces Issuance of Stock Options
Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript
Microbix Reports Results for Q1 2026
Microbix Welcomes The College of American Pathologists as a Client For Supply of QAPs for PT/EQA Programs
Microbix Schedules Release of Results for Q1 Fiscal 2026
Microbix Presents Molecular Pathology Platform Results
Microbix Updates Investor Presentation on its Website
Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing
Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript